What is VRTX stock price target for 2026?

WallStSmart's 12-month price target for Vertex Pharmaceuticals Inc is $450.07, representing 5.3% upside from the current price of $427.38.

What is VRTX stock forecast?

Vertex Pharmaceuticals Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is VRTX undervalued based on price targets?

Our DCF intrinsic value for Vertex Pharmaceuticals Inc is $976.24, against a current price of $427.38. The margin of safety is 56.65%.

VRTX

Vertex Pharmaceuticals Inc

NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY

$427.38

+0.98% today

Updated 2026-04-29

Market cap

$109.50B

P/E ratio

28.10

P/S ratio

9.12x

EPS (TTM)

$15.32

Dividend yield

—

52W range

$363 – $511

Volume

1.3M

Market cap

$109.50B

P/E ratio

28.10

P/S ratio

9.12x

EPS (TTM)

$15.32

Dividend yield

—

52W range

$363 – $511

Volume

1.3M

Vertex Pharmaceuticals Inc (VRTX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$427.38

Consensus

$539.08

+26.14%

2030 Target

—

DCF

$976.24

+56.65% MoS

Current price

$427.38

Analyst consensus

$539.08

+26.14%

2030 Target

—

Intrinsic (DCF)

$976.24

+56.65% MoS

29 analysts:

12 Buy7 Hold2 Sell

Management guidance

No specific CEO revenue targets found in provided data. Management has not publicly stated explicit revenue guidance for 2026-2030 periods. Analyst consensus points to $13.3B (2026) and $14.66B (2027), with Simply Wall Street projecting $16.0B by 2029.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$1,316.13

—

Base case (2030)

$789.68

—

Bear case (2030)

$526.45

—

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)
Revenue	$9.9B	$11.0B	$12.1B	$13.3B	$14.7B	$15.8B	$16.9B
Revenue growth	—	11.7%	9.6%	10.8%	10.3%	7.8%	7.0%
EPS	$15.22	$0.29	$18.41	$19.39	$22.05	$24.50	$26.80
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$614.19	$658.07	$745.81	$789.68

Catalysts & risks

Growth catalysts

+ FDA label expansions for ALYFTREK and TRIKAFTA expanding CF eligibility to 95% of US CF patients (completed April 2026)

+ Povetacicept BLA submission for IgA Nephropathy (IgAN) with priority review voucher reducing FDA review to 6 months

+ Phase 3 RAINIER trial success in kidney disease showing positive Week 36 interim results on primary and secondary endpoints

+ JOURNAVX pain management data demonstrating effective post-operative pain control

+ Pipeline expansion beyond core CF franchise diversifying revenue streams and reducing single-asset dependency

Key risks

- CF market saturation and patient population ceiling limiting long-term CF revenue growth despite label expansions

- Execution risk on new pipeline programs (IgAN, kidney disease) with uncertain peak sales and market uptake

- Pricing pressure and competitive threats from other CFTR modulators and new therapeutic classes

- Insider selling signal (EVP Joy Liu sold $439K in stock April 1, 2026) suggests potential management concerns

- High valuation (29.2x P/E, 9.29x P/S) leaves limited margin for error on growth assumptions

Methodology

Vertex Pharmaceuticals Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 29 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.